Nootropic compositions and methods of providing or using the same are provided herewith. Some preferred compositions include a combination of free amino acids and one or more peptides. Compositions may optionally include one or more of an anti-adherent, a B vitamin, shilajit, a sugar, a fatty acid, ashwaganda, ginseng, or rodiola, among other things.

Nootropic compositions and methods of providing or using the same are provided herewith. Some preferred compositions include a combination of free amino acids and one or more peptides. Compositions may optionally include one or more of an anti-adherent, a B vitamin, shilajit, a sugar, a fatty acid, ashwaganda, ginseng, or rodiola, among other things.

A composition and method for administering an active agent to a pet, such as a dog, a cat or a horse. The composition may comprise a yogurt-based chewable delivery matrix and a plurality of water-soluble film pieces dispersed throughout the chewable delivery matrix. The composition may also comprise a delivery matrix having at least 15% by weight of crude protein and a plurality of water-soluble film pieces dispersed throughout the delivery matrix. The plurality of water-soluble film pieces encompass an active agent therein, wherein the active agent is rapidly released from the composition upon contact with saliva from the pet. At least a portion of the released active agents may be oromucosally absorbed by the pet.

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

A method of treating vaginal dryness by administering a vaginal care composition, which includes an effective amount of a vaginal care agent, to vaginal tissue of a user experiencing vaginal dryness. The vaginal care agent may be selected to specifically treat symptoms of vaginal dryness exhibited by the introitus and/or labia, based on the transcriptomic data of skin cells obtained therefrom. In some instances, the vaginal care composition may be applied to introitus and/or labia with a suitable implement configured for such use.

A method of treating vaginal dryness by administering a vaginal care composition, which includes an effective amount of a vaginal care agent, to vaginal tissue of a user experiencing vaginal dryness. The vaginal care agent may be selected to specifically treat symptoms of vaginal dryness exhibited by the introitus and/or labia, based on the transcriptomic data of skin cells obtained therefrom. In some instances, the vaginal care composition may be applied to introitus and/or labia with a suitable implement configured for such use.

Provided are pharmaceutical compositions for skin lightening, which are particularly useful in treating skin hyperpigmentation, together with methods for their use. The compositions comprise glutathione conjugated to a peptide having a sequence comprising PKEK (SEQ ID NO: 1) and cysteamine or a pharmaceutical salt thereof.

Disclosed is a composition for preventing, treating or ameliorating a viral infection disease, which is safe for human application since the safety of a reactive oxygen species production inhibitor and a reactive oxygen species scavenger has already been verified. The disclosure utilizes inversely the mechanism of viruses which induces oxidative damage of a host cell and then activates viral replication and infection. Although not having direct specificity to a specific virus like existing vaccines, the composition can effectively inhibit proliferation of all viruses including oxidative stress, regardless of virus type or mutations. It can be applied as a sub-universal infection inhibitor and therapeutic agent as a limited alternative to vaccines that must be newly developed each year due to emergence of new viruses or viral mutations, and is expected to be used as a preventive agent or auxiliary agent to prevent epidemics.

Compositions and methods for modulating inflammation and wound healing are provided.